A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Paclitaxel in the Treatment of Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Navitoclax (Primary) ; Paclitaxel
- Indications Brain metastases; Solid tumours
- Focus Adverse reactions
- Sponsors Abbott Laboratories
- 07 Aug 2012 Actual end date Jul 2012 added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Apr 2012 Planned end date changed from 1 Dec 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.